Table 3 Active clinical trials concerning to post- COVID-19 syndrome

COVID-19

Long-term morbidities and sequels of SARS-CoV-2 infections in the general population (NAPKON-POP)

Observational on 2000 participants (estimated)

NCT04679584, recruiting

COVID-19, Cardiac Disease

Sequelae (organ dysfunction) after COVID-19 (12 months)

Observational on 120 participants (estimated)

NCT04442789, recruiting

COVID-19, Hypertension

Average 24 hour Ambulatory Blood Pressure Monitoring - Systolic Blood Pressure, (all day and night) at 12 months in SARS-CoV-2 cases

Observational on 150 participants (estimated)

NCT05087290, recruiting

COVID-19

Native myocardial T1 relaxation time (MRI) at 12 weeks post COVID-19 diagnosis

Observational on 215 participants (actual enrolment)

NCT04525404, active, not recruiting

COVID-19

Presence of at least one clinical, biological and/or imaging cardiovascular anomaly within 1 month of recovering

Observational on 200 participants (estimated)

NCT04452630, recruiting

COVID-19

Incidence of major cardiovascular events (congestive heart failure, myocardial infarction, cardiomyopathy and ischemic stroke) and of atrial arrhythmia, 12 months post-COVID-19

Observational (Patient Registry) on 100 participants (estimated)

NCT04605965, recruiting

COVID-19

Echocardiographic strain measurements of the left, right heart and vascular ultrasound findings up to 12 months

Observational on 250 participants (estimated)

NCT04756193, recruiting

COVID-19, ARDS

Evaluation of evolution of renal and right and left myocardic functions during first year after ICU discharged in population studied

Observational on 150 participants (estimated)

NCT04401111, recruiting

COVID-19, AKI

GFR loss at 6 months post-hospital admission, Cystatin C as indicator of mortality, respiratory illness and disease severity at 30 days post-hospital admission

Observational (Patient Registry) on 900 participants (estimated)

NCT04353583, recruiting

COVID-19, Kidney Transplant

Predictive value of IL-6 contents of whole blood samples after ex vivo stimulation with LPS and ATP over 10 months

Interventional (Clinical Trial) on 115 participants (estimated)

NCT04369456, recruiting

COVID-19, AKI, CKD, ESRD, Transplant, Failure, Kidney

AKI incidence from hospital admission through hospital discharge up to 24 weeks, dialysis requirement through study completion up to 1 year from enrolment, hospital mortality within 1 year, renal functional recovery assessed at 3, 6 and 12 months from enrolment at hospital admission

Observational on 2000 participants (estimated)

NCT04491227, Enrolling by invitation